A smartphone-based hemoglobin (Hgb) assessment application quantitatively analyzes pallor in patient-sourced photos using image analysis algorithms to enable a noninvasive, accurate quantitative smartphone app for detecting anemia. A user takes a photo of his/her fingernail beds using the app and receives an accurate displayed Hgb level. Since fingernails do not contain melanocytes, the primary source of color of these anatomical features is blood Hgb. At the same time, quality control software minimizes the impact of common fingernail irregularities (e.g. leukonychia and camera flash reflection) on Hgb level measurement. Metadata recorded upon capturing the image is leveraged for determining a users' Hgb level thereby eliminating the need for external equipment. A personalized calibration of image data with measured Hgb levels improves the accuracy of the application.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
This disclosure relates to methods of treating bronchiectasis comprising administering an effective amount of a cystic fibrosis drug to a subject. In certain embodiments, the subject is diagnosed with non-CF bronchiectasis and the subject is diagnosed with moderate elevated sweat chloride and optionally pancreatic sufficiency. In certain embodiments, a sample of the subject is tested for presence of a known cystic fibrosis transmembrane conductance regulator mutation and no mutation is identified in the sample, thereby providing a subject diagnosed without a known cystic fibrosis transmembrane conductance regulator mutation. In certain embodiments, this disclosure relates to methods of bronchiectasis treatment by managing symptoms such as slowing decline in lung function and preventing exacerbations.
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
3.
Methods, Devices and Systems for Enhanced Transduction Efficiency
The systems and methods are directed to leveraging the channel geometry and configuration to overcome diffusion limitations of current transduction systems. The methods may include a method of transducing target cells using a device. The device may include at least one continuous channel. The method may include delivering target cells and viral vectors into a transduction region of the channel. After transducing for some incubation time, a flushing solution may be delivered. The method may include collecting transduced cells after the transducing incubation time and the delivering of the flushing solution.
The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present disclosure relates to systems and methods for nucleic acid storage that can be used under ambient conditions economically. In one implementation, the system may include a cartridge. The cartridge may include a first surface and a second surface opposing the first surface. The cartridge may include a chamber disposed (i) parallel to the first surface and the second surface and (ii) between the first surface and the second surface. The chamber may be configured to receive a blotter substrate. The cartridge may also include at least one opening disposed in the first surface above and interfaces with the chamber. The opening may be configured to receive a permeable membrane.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
Disclosed herein are compositions and methods for managing respiratory syncytial virus (RSV) infections. In certain embodiments, vaccines and pharmaceutical compositions comprise or encode an RSV G protein comprising a mutation or fusion protein arrangement disclosed herein. In certain embodiments, virus particles/virus like particles, nucleic acids, vectors, or attenuated RSV vaccines are used in methods reported herein.
Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed herein are recombinant asparaginases with ancestral variant sequences for uses as therapeutics. In certain embodiments, it is contemplated that the ancestral variant asparaginases have reduced immunogenicity thereby preventing or reducing the risk of host inactivation and/or anaphylaxis. In certain embodiments, this disclosure relates to treating diseases associated with asparagine dependence comprising administering an effective amount of an ancestral variant asparaginase or conjugate disclosed herein to a subject in need thereof.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
9.
Methods, Devices and Systems for Generating a Chemical Gradient
The systems, devices, and methods utilize devices configured to generate multiple gradients of a plurality of different drugs in x and y coordinates at the same time so as to provide multiple drug concentrations and/or combinations. A device may include a first layer having a first set of one or more inlets in fluid communication with stem channels and a plurality of chambers, and a second layer having a second set of one or more inlets in fluid communication with stem channels and a plurality of chambers. The second layer may be disposed above the first layer so that the first set and the second set of inlets are offset and the plurality of chambers of the first and second layers align and overlap. The device may include a plurality of wells defined by the aligned the plurality of chambers of the first layer and the second layer.
The systems and methods of the disclosure can include an insert that can form an enclosed chamber within a well so that a mixture of cells and vectors can be uniformly spread within the enclosed chamber to a constrained height. In some examples, the system may include at least one insert. Each insert configured to be disposed within a well of a culture device. Each insert may have a first end and a second end. The second end may be configured to contact a bottom surface of the culture device. Each insert may include a chamber within the second end or the culture device may include a chamber within the bottom surface so that an enclosed chamber is formed when the insert is disposed on the bottom surface of the well. The enclosed chamber may be configured to constrain a transduction mixture to a height defined by the chamber.
B65D 81/22 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient in moist conditions or immersed in liquids
B65D 81/24 - Adaptations for preventing deterioration or decay of contentsApplications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
B65D 85/30 - Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure
B65D 85/50 - Containers, packaging elements or packages, specially adapted for particular articles or materials for living organisms, articles or materials sensitive to changes of environment or atmospheric conditions, e.g. land animals, birds, fish, water plants, non-aquatic plants, flower bulbs, cut flowers or foliage
11.
SYSTEMS AND METHODS FOR OPTIMIZING PARAMETERS FOR TARGETED CELL TRANSDUCTION OUTCOMES
The devices, systems, and methods may include can provide optimization and standardization of transduction parameters. The method may determine optimized transduction parameters. The method may include receiving (i) specifications for one or more transduction outcomes; and (ii) bulk transduction outcomes for one or more transductions of cells with a viral vector using at least one transduction parameter. The specifications may include a target number of vector integrations per cell. The method may include generating a model for each bulk transduction outcome to determine each bulk transduction outcome associated with a range of values of the at least one transduction parameter. The method may include generating distributions of vector integrations per cell for each value of the transduction parameter using the associated modeled bulk transduction outcomes. The method may also include determining an optimized transduction parameter for each transduction parameter from the distributions of vector integrations based on the specifications.
This disclosure relates to methods of treating cancer using MDM2 inhibitors disclosed herein, and pharmaceutical compositions related thereto. In certain embodiments, this disclosure relates to methods of treating cancer, such as hematological cancers comprising administering an effective amount of a MDM2 inhibitor to a subject in need thereof. In certain embodiments, the MDM2 inhibitor is sabizabulin and the hematological cancer is acute myeloid leukemia.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61P 35/02 - Antineoplastic agents specific for leukemia
13.
USES OF ADRENALONE TO MANAGE CARDIOTOXICITY OR CARDIOVASCULAR DISORDERS
This disclosure relates to methods of treating or preventing cardiotoxicity or a cardiac disease or condition by administering adrenalone, derivative, prodrug, ester, or salt thereof to a subject in need thereof. In certain embodiments, the subject is in need thereof due to administration of or consumption of addictive substances or therapeutic agents that poses a risk of cardiotoxicity.
An exemplary embodiment of the present disclosure provides a halo intrinsic traction (HIT) system, comprising a first support, a second support, and a first actuator. The first support can be configured to attach to a head portion of a patient. The second support can be configured to attach to a body portion of a patient, the body portion being below the head portion. The first actuator can be configured to generate an expansion force between the first and second supports.
Disclosed herein are methods of treating or preventing respiratory diseases or conditions such as rhinosinusitis, chronic obstructive pulmonary disease, or bronchiectasis in a subject with or without cystic fibrosis (CF). In certain embodiments, this disclosure relates pharmaceutical compositions having compounds disclosed herein and uses thereof. In certain embodiments, the compound is a phosphodiesterase (PDE) 4 inhibitor. In certain embodiments, the compound is 3-(2-bromo-5-methoxyphenyl)-6-isopropyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (HDCF-104), 6-(3,4-dimethoxyphenyl)-3-ethyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine (uHTS-159), derivatives, or salts thereof.
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This disclosure reports methods of improving tissue wound healing or growing tissues by using biodegradable graft compositions optionally comprising an exogenously added beneficial bacteria and optionally comprising exogenously added isolated macrophages or other cells. In certain embodiments, this disclosure relates to surgical methods of improving the healing of oral issues after a surgical intervention by implanting graft compositions reported herein on, in, or around the surgical site.
A passive implantable medical device for controlling a flow of fluid through a tube within a patient includes a first component and a second component movably coupled to one another and defining a central passage configured for receiving a portion of the tube therethrough. The passive implantable medical device is configured for moving between a first configuration and a second configuration to constrict a portion of the tube. An active implantable medical device for controlling a flow of a first fluid through a tubing includes a flow control cuff comprising a stiff outer wall and a deformable inner wall which defines a central opening sized such that the tubing can extend therethrough. A pump is configured to modulate a pressure of the second fluid within the interior space to apply a constrictive force to a section of the tubing.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
18.
INTERFERON GAMMA-PRIMED MESENCHYMAL STROMAL CELLS AS PROPHYLAXIS FOR GRAFT VERSUS HOST DISEASE
The present disclosure provides composition and methods comprising interferon γ-primed human mesenchymal stromal cells (γMSCs) for preventing or reducing the likelihood of Graft Versus Host Disease (GVHD) or a symptom thereof in a human subject that has been administered a hematopoietic stem cell transplant (HCT).
This disclosure relates to SARS-CoV-2 antibodies disclosed herein and specific binding fragments thereof, therapeutic and diagnostic uses, and compositions related thereto. In certain embodiments, this disclosure relates to antibodies disclosed herein and specific binding fragments thereof wherein the antibody or fragment specifically binds to an epitope expressed on a SARS-CoV-2 particle such as the spike protein or receptor binding domain. In certain embodiments, this disclosure relates to treating or preventing a SARS-CoV-2 or related coronavirus infection comprising administering an effective amount of an antibody disclosed herein or specific binding fragments thereof to a subject in need thereof.
Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are isolated prenatally, at birth, or after the subject's birth. The modified MSC may also express high levels von Willebrand factor protein.
High-throughput co-culture models, for example, relevant to the cell barrier interface, are disclosed that employ under-side cell seeding in a miniaturized and automated system and process. The seeding method, which can be implemented in a scalable and low-cost manner, can eliminate the need for an inversion process by adjusting/optimizing the density of the cell suspension medium to float cells of interest so they can attach under a membrane.
This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac symptoms, conditions that result from endothelial dysfunction, altered T-cell function/immune dysregulation, mitochondrial dysfunction, and/or and other complications often associated with coronavirus or other viral infections.
The implanted pressure sensors can non-invasively and stably measure intracranial pressure using MRI-compatible materials. In some examples, the implanted pressure sensor can include a fluid reservoir filled with a fluid. The sensor may also include a gas chamber filled with a gas and a gas-fluid interface. The interface may include a channel. The channel may have a first end and a second end. The channel may have a pattern that includes a plurality of linear segments connected by a plurality of junction segments. The fluid reservoir may be in flow communication with the gas-fluid interface. The gas chamber may be in flow communication with the gas-fluid interface and spaced separate from the gas-fluid interface.
Systems, devices, and methods are described for assessing the risk of developmental, cognitive, social, or mental abilities or disabilities in very young patients (e.g., in the first 2-6 months of life). Generally, the decline in visual fixation of a subject over time with respect to certain dynamic stimuli provides a marker of possible abilities or disabilities (such as ASD). The visual fixation of the subject is identified, monitored, and tracked over time through repeated eye tracking sessions, and data relating to the visual fixation is then analyzed to determine a possible increased risk certain conditions in the subject. A change in visual fixation as compared to similar visual fixation data of typically-developing subjects or to a subject's own, prior visual fixation data provides an indication of a developmental, cognitive, or mental ability or disability.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 5/16 - Devices for psychotechnicsTesting reaction times
25.
RSV VACCINES WITH TRUNCATED G-PROTEIN MUCIN DOMAINS
The disclosure relates to Respiratory Syncytial Virus (RSV) vaccine compositions having truncated mucin domains in the G-protein. In certain embodiments, this disclosure relates to virus particles, virus-like particles, virosomes, nucleic acids, vectors, or attenuated live RSV vaccines for uses reported herein. In certain embodiments, this disclosure relates to methods of vaccinating, treating, or preventing RSV infections by administering to a subject in need thereof an effective amount of a composition disclosed herein.
Systems, devices, and methods are described for assessing the risk of developmental, cognitive, social, or mental abilities or disabilities in very young patients (e.g., in the first 2-6 months of life). Generally, the decline in visual fixation of a subject over time with respect to certain dynamic stimuli provides a marker of possible abilities or disabilities (such as ASD). The visual fixation of the subject is identified, monitored, and tracked over time through repeated eye tracking sessions, and data relating to the visual fixation is then analyzed to determine a possible increased risk certain conditions in the subject. A change in visual fixation as compared to similar visual fixation data of typically-developing subjects or to a subject's own, prior visual fixation data provides an indication of a developmental, cognitive, or mental ability or disability.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 5/16 - Devices for psychotechnicsTesting reaction times
27.
LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS ENCODING THERAPEUTIC GENES AND USES IN MEDICAL METHODS
This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Multi-lumen catheters with first and second expandable members are configured so that one expandable member dilates the Sphincter of Oddi and the second anchors within the biliary duct distal to the Common Bile Duct/Cystic Duct junction or within the cystic duct. The multi-lumen catheters include a primary lumen sized and configured for delivering a flushing agent to remove gallstones together or separately with a dye to complete a Cholangiogram and also include at least one lumen in fluid communication with the first and second expandable members.
This disclosure relates to therapeutics containing IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are method of treating hemophilia A in a subject comprising injecting the subject with mesenchymal stromal/stem cells (MSC) modified to express high levels of Factor VIII protein. The MSC are injected into the subject prenatally. The modified MSC may also express high levels von Willebrand factor protein.
Provided herein are compounds, pharmaceutical compositions including such compounds, and methods of using such compounds to treat diseases or disorders associated with MDM2 activity.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
32.
Nutritional Formulas Comprising Medium Chain Fatty Acids or Esters Thereof and Methods Related Thereto
Disclosed are nutritional formulations and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordination difficulties. In certain embodiments, the nutritional formulations comprise medium chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
33.
Methods and Devices for Inducement of Sweat for Medical Diagnostics
Methods and devices are provided for sweat inducement, which is useful in diagnostics, such as diagnosis of cystic fibrosis in a patient. The method includes applying a microneedle patch, which comprises microneedles which comprise pilocarpine or another sweat-inducing agent, to the skin of the patient effective to cause the microneedles to penetrate across the epidermis and into the dermis releasing the pilocarpine or another sweat-inducing agent into the skin in an amount effective to induce secretion of sweat from the skin. The secreted sweat can be collected and analyzed, for example by measuring chloride concentration in the sweat, which may be indicative of cystic fibrosis.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
34.
FLUID DELIVERY CONNECTOR PROTECTION DEVICES AND METHODS
Systems, methods, and devices for prohibiting contaminants from entering a central venous catheter connection are disclosed. A device described herein includes a first body section defining a first internal cavity and a second body section defining a second internal cavity. The second body section can be hingeably connected to the first body section. A first tubing notch is positioned at an end of at least one of the first body section or the second body section. The device has an open configuration and a closed configuration, and wherein, in the closed configuration, the first internal cavity and the second internal cavity are adjacent to create a connector cavity configured to contain a first connector.
The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/11 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring interpupillary distance or diameter of pupils
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/16 - Devices for psychotechnicsTesting reaction times
36.
RECOMBINANT INTERLEUKIN-37, CHIMERIC ANTIGEN RECEPTORS, NUCLEIC ACIDS, AND VECTORS ENCODING THE SAME AND USES IN CANCER THERAPIES
This disclosure relates to therapeutics containing recombinant IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.
This disclosure relates to compounds, pharmaceutical compositions, and methods of treating or preventing sickle cell disease or conditions associated thereto. In certain embodiments, the compounds are 1-(thiazol-2-yl)urea derivatives. In certain embodiments, the compounds are 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivatives. In certain embodiments, the compounds are 1-phenyl-1H-pyrrole-2,5-dione derivatives. In certain embodiments, this disclosure relates to methods of treating or preventing sickle cell disease or condition associated thereto comprising administering an effective amount of a 1-(thiazol-2-yl)urea derivative, or 1-phenyl-1H-pyrrole-2,5-dione derivative, or a 1-(9H-carbazol-9-yl)-3-mercaptopropan-2-ol derivative as disclosed herein to a subject in need thereof.
Disclosed herein are novel variants of clotting factor IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.
This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating, encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
Methods and systems for treatment of feeding disorders in individuals by a multidisciplinary team comprising medical, behavioral, nutritional, and oral-motor skill professionals and/or specialists. For example, in one embodiment, a subject may go through treatment that comprises four phases/process: screening, assessment, intervention, and discharge. The screening process may determine the subject’s eligibility for the treatment. The assessment process may establish a baseline from which the specific treatment is determined. The intervention process generally implements the treatment through daily “doses” of treatment meal sessions. The discharge process may ensure that the treatment gains made during the intervention phase are carried into the subject’s daily life.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
41.
METHODS AND SYSTEMS FOR TREATMENT OF FEEDING DISORDERS
Methods and systems for treatment of feeding disorders in individuals by a multi-disciplinary team comprising medical, behavioral, nutritional, and oral-motor skill professionals and/or specialists. For example, in one embodiment, a subject may go through treatment that comprises four phases/process: screening, assessment, intervention, and discharge. The screening process may determine the subject's eligibility for the treatment. The assessment process may establish a baseline from which the specific treatment is determined. The intervention process generally implements the treatment through daily “doses” of treatment meal sessions. The discharge process may ensure that the treatment gains made during the intervention phase are carried into the subject's daily life.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
42.
METHODS AND SYSTEMS FOR TREATMENT OF FEEDING DISORDERS
Methods and systems for treatment of feeding disorders in individuals by a multidisciplinary team comprising medical, behavioral, nutritional, and oral-motor skill professionals and/or specialists. For example, in one embodiment, a subject may go through treatment that comprises four phases/process: screening, assessment, intervention, and discharge. The screening process may determine the subject’s eligibility for the treatment. The assessment process may establish a baseline from which the specific treatment is determined. The intervention process generally implements the treatment through daily “doses” of treatment meal sessions. The discharge process may ensure that the treatment gains made during the intervention phase are carried into the subject’s daily life.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
43.
Galectin-9 Specific Binding Agents for Use in Treating Cancer
This disclosure relates to uses of galectin-9 specific binding agents and chimeric antigen receptors in methods of treating cancer such as hematological cancers or solid tumors. In certain embodiments, the galectin-9 specific binding agent is a TIM3, CD44, CD40, CLEC7a (Dectin-1), or CD137 (4- IBB) extracellular domain, an anti-galectin-9 antibody, specific binding single chain antibody, fragment, or variant thereof. In certain embodiments, cancer treatment is a cell-based therapy using chimeric antigen receptors having a galectin-9 targeting sequence.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.
This disclosure relates to methods of preserving mesenchymal stromal/stem cells (MSCs) for use in clinical applications. In certain embodiments, this disclosure relates to methods of preserving MSCs comprising mixing MSCs with interferon-gamma prior to cryopreserving, freezing, or cooling the MSCs to a temperature below zero degrees Celsius.
This disclosure relates to methods for identifying molecular arrangements useful in managing diseases or conditions. In certain embodiments, this disclosure relates to treating an immune regulated disease comprising administering to a subject in need thereof an effective amount of a grouped molecular arrangement comprising a specific binding agent to CD19, a specific binding agent to CD3, and IL-12. In certain embodiments, this disclosure relates to screening test compounds comprising providing a library of multifunctional binding specificities and contacting the library with cells to evaluate in vitro therapeutic potential.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
This disclosure relates to methods of treating bronchiectasis comprising administering an effective amount of a cystic fibrosis drug to a subject. In certain embodiments, the subject is diagnosed with non-CF bronchiectasis and the subject is diagnosed with moderate elevated sweat chloride and optionally pancreatic sufficiency. In certain embodiments, a sample of the subject is tested for presence of a known cystic fibrosis transmembrane conductance regulator mutation and no mutation is identified in the sample, thereby providing a subject diagnosed without a known cystic fibrosis transmembrane conductance regulator mutation. In certain embodiments, this disclosure relates to methods of bronchiectasis treatment by managing symptoms such as slowing decline in lung function and preventing exacerbations.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
This disclosure relates to methods of treating bronchiectasis comprising administering an effective amount of a cystic fibrosis drug to a subject. In certain embodiments, the subject is diagnosed with non-CF bronchiectasis and the subject is diagnosed with moderate elevated sweat chloride and optionally pancreatic sufficiency. In certain embodiments, a sample of the subject is tested for presence of a known cystic fibrosis transmembrane conductance regulator mutation and no mutation is identified in the sample, thereby providing a subject diagnosed without a known cystic fibrosis transmembrane conductance regulator mutation. In certain embodiments, this disclosure relates to methods of bronchiectasis treatment by managing symptoms such as slowing decline in lung function and preventing exacerbations.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61P 11/00 - Drugs for disorders of the respiratory system
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
49.
Methods of Producing Specialized Cardio-Like Cells from Stem Cells
This disclosure relates to method of differentiating stem cells to specific cardiac-like cells. In certain embodiments, the disclosure contemplates methods of generating left ventricular-like cells and the atrial-like cells by timing the exposure of dividing stem cells to retinoic acid (RA) or retinoic acid receptor inhibitors.
This disclosure relates to methods of treating cancer using liposomal particles and pharmaceutical compositions related thereto. In certain embodiments, the anticancer agent is trans-4-[2-[(2-cyclopropylethyl)amino]-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexanol (MRX-2843) or salt thereof optional in combination with another chemotherapy agent.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
51.
POLYPEPTIDES THAT BIND TO VON WILLEBRAND FACTOR (VWF) AL DOMAIN OR AN AUTOINHIBITORY MODULE, VARIANTS, AND USES THEREOF
This disclosure relates to polypeptides comprising an immunoglobulin single variable domain that specifically binds an autoinhibitory module on the C terminal end or on the N terminal end of von Willebrand Factor (VWF) A1 domain or the von Willebrand Factor (VWF) A1 domain. In certain embodiments this disclosure relates to uses of polypeptides disclosed herein for treating or preventing bleeding or abnormal blood clotting and diseases or conditions related thereto.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/36 - Blood coagulation or fibrinolysis factors
52.
ANTIBODIES THAT INHIBIT GLYCOPROTEIN IB-IX MEDIATED PLATELET SIGNALING AND USES IN MANAGING BLEEDING CONDITIONS
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
UNIVERSITE DE STRASBOURG (France)
Inventor
Li, Renhao
Chen, Wenchun
Wilson, Moriah Simone
Lanza, François
Abstract
This disclosure relates to antibodies that inhibit glycoprotein Ib-IX-mediated platelet signaling and clearance. In certain embodiments, this disclosure relates to recombinant chimeric antibodies or antibody fragments comprising one or more complementarity determining regions (CDRs) of antibodies disclosed herein. In certain embodiments, this disclosure relates to methods of treating or preventing glycoprotein Ib-IX-mediated bleeding disorders or conditions using antibodies or fragments disclosed herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This disclosure relates to wild boar cathelicidin peptides, fragments, variants, and derivatives thereof, and vectors encoding that same, as reported herein for uses in the prevention or treatment of viral infections such as coronavirus infections. In certain embodiments, the subject is a human subject exhibiting symptoms of, at risk of, or diagnosed with a coronaviral infection such as SARS-CoV2.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
It is an object of this disclosure to provide systems, devices, and methods for the direct use of fluorescent reporters that measure multiaxial and dynamic shear flows that occur invitro or in vivo across a surface of interest, where shear flows canbe measured, quantified and/or correlated to physiological changes in cells or tissues in real time. In certain embodiments, this disclosure contemplates imaging or visualizing the shear field applied to a surface, e.g., a surface of cells or inner lining of a blood vessel, the lumen of pumping lymphatics, within the bile duct, vessels with significant leakage, inflamed endothelium, tumor vasculature, or other systems.
This disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme or a vector encoding expression thereof, and a prodrug cleaved by said purine cleaving enzyme. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme, or a vector encoding expression thereof, in the absence of a prodrug cleaved by said purine cleaving enzyme.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical research services Healthcare services; pediatric healthcare services; providing information relating to child and family health, wellness, and nutritional issues via the internet
57.
Particles for targeted delivery and uses in managing bleeding or blood clotting
This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.
In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically, the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.
Systems, devices, and methods are described for assessing the risk of developmental, cognitive, social, or mental abilities or disabilities in very young patients (e.g., in the first 2-6 months of life). Generally, the decline in visual fixation of a subject over time with respect to certain dynamic stimuli provides a marker of possible abilities or disabilities (such as ASD). The visual fixation of the subject is identified, monitored, and tracked over time through repeated eye tracking sessions, and data relating to the visual fixation is then analyzed to determine a possible increased risk certain conditions in the subject. A change in visual fixation as compared to similar visual fixation data of typically-developing subjects or to a subject's own, prior visual fixation data provides an indication of a developmental, cognitive, or mental ability or disability.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
60.
USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS
This disclosure relates to method of treatment and prevention of cardiovascular complications in kidney disease comprising administering an arginase inhibitor to a subject in need thereof. In certain embodiments, the arginase inhibitor is administered in combination with L-arginine. In certain embodiments, the arginase inhibitor is administered in combination with L-arginine and tetrahydrobiopterin. In certain embodiments, the arginase inhibitor is administered in combination with tetrahydrobiopterin. In certain embodiments, the subject is diagnosed with kidney disease. In certain embodiments, the subject is diagnosed with kidney disease and a cardiovascular disease or condition.
A passive implantable medical device for controlling a flow of fluid through a tube within a patient includes a first component and a second component movably coupled to one another and defining a central passage configured for receiving a portion of the tube therethrough. The passive implantable medical device is configured for moving between a first configuration and a second configuration to constrict a portion of the tube. An active implantable medical device for controlling a flow of a first fluid through a tubing includes a flow control cuff comprising a stiff outer wall and a deformable inner wall which defines a central opening sized such that the tubing can extend therethrough. A pump is configured to modulate a pressure of the second fluid within the interior space to apply a constrictive force to a section of the tubing.
Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/51 - Bone morphogenic factorOsteogeninOsteogenic factorBone-inducing factor
63.
MANAGING THE ACUTE AND LONG-TERM EFFECTS OF CORONAVIRAL INFECTIONS AND COMPOSITIONS RELATED THERETO
This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac symptoms, conditions that result from endothelial dysfunction, altered T-cell function/immune dysregulation, mitochondrial dysfunction, and/or and other complications often associated with coronavirus or other viral infections.
This disclosure relates to SARS-CoV-2 antibodies disclosed herein and specific binding fragments thereof, therapeutic and diagnostic uses, and compositions related thereto. In certain embodiments, this disclosure relates to antibodies disclosed herein and specific binding fragments thereof wherein the antibody or fragment specifically binds to an epitope expressed on a SARS-CoV-2 particle such as the spike protein or receptor binding domain. In certain embodiments, this disclosure relates to treating or preventing a SARS-CoV-2 or related coronavirus infection comprising administering an effective amount of an antibody disclosed herein or specific binding fragments thereof to a subject in need thereof.
High-throughput co-culture models, for example, relevant to the cell barrier interface, are disclosed that employ underside cell seeding in a miniaturized and automated system and process. The seeding method, which can be implemented in a scalable and low-cost manner, can eliminate the need for an inversion process by adjusting/optimizing the density of the cell suspension medium to float cells of interest so they can attach under a membrane.
Multi-lumen catheters with first and second expandable members are configured so that one expandable member dilates the Sphincter of Oddi and the second anchors within the biliary duct distal to the Common Bile Duct/Cystic Duct junction or within the cystic duct. The multi-lumen catheters include a primary lumen sized and configured for delivering a flushing agent to remove gallstones together or separately with a dye to complete a Cholangiogram and also include at least one lumen in fluid communication with the first and second expandable members.
The systems, devices, and methods utilize devices configured to generate multiple gradients of a plurality of different drugs in x and y coordinates at the same time so as to provide multiple drug concentrations and/or combinations. A device may include a first layer having a first set of one or more inlets in fluid communication with stem channels and a plurality of chambers, and a second layer having a second set of one or more inlets in fluid communication with stem channels and a plurality of chambers. The second layer may be disposed above the first layer so that the first set and the second set of inlets are offset and the plurality of chambers of the first and second layers align and overlap. The device may include a plurality of wells defined by the aligned the plurality of chambers of the first layer and the second layer.
The systems and methods of the disclosure can rapidly and automatically determine and monitor tracking events by generating event codes using messages from multiple source systems within the healthcare ecosystem. The method may include detecting one or more healthcare data messages of a plurality of types of healthcare data messages associated with healthcare of a patient. The method may include extracting text of each message of the first type and processing the extracted text of each message to determine one or more units of text. The method may include determining one or more tracking events by applying one or more trained models to each unit of text of each message. The method may include storing one or more event codes corresponding to the one or more tracking events and its associated deadline in a record for the patient of the tracking event database.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
69.
INTERLEUKIN-37, CHIMERIC ANTIGEN RECEPTORS, NUCLEIC ACIDS, AND VECTORS ENCODING THE SAME AND USES IN CANCER THERAPIES
This disclosure relates to therapeutics containing IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.
Methods and devices are provided for sweat inducement, which is useful in diagnostics, such as diagnosis of cystic fibrosis in a patient. The method includes applying a microneedle patch, which comprises microneedles which comprise pilocarpine or another sweat-inducing agent, to the skin of the patient effective to cause the microneedles to penetrate across the epidermis and into the dermis releasing the pilocarpine or another sweat-inducing agent into the skin in an amount effective to induce secretion of sweat from the skin. The secreted sweat can be collected and analyzed, for example by measuring chloride concentration in the sweat, which may be indicative of cystic fibrosis.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
71.
METHODS AND DEVICES FOR INDUCEMENT OF SWEAT FOR MEDICAL DIAGNOSTICS
Methods and devices are provided for sweat inducement, which is useful in diagnostics, such as diagnosis of cystic fibrosis in a patient. The method includes applying a microneedle patch, which comprises microneedles which comprise pilocarpine or another sweat-inducing agent, to the skin of the patient effective to cause the microneedles to penetrate across the epidermis and into the dermis releasing the pilocarpine or another sweat-inducing agent into the skin in an amount effective to induce secretion of sweat from the skin. The secreted sweat can be collected and analyzed, for example by measuring chloride concentration in the sweat, which may be indicative of cystic fibrosis.
The systems, devices, and methods utilize devices configured to (i) control the loading of each channel layer and/or (ii) prevent formation of bubbles within the channels. A device may include two or more stacked layers. The two or more stacked layers may include a first layer and a second layer. The first entry region diameter of the first layer and the second entry region diameter of the second layer may be different; and/or the first exit region diameter of the first layer and the second exit region diameter of the second layer may be different; and/or one or more of the first channel dimensions (e.g., length and/or width) of the first layer and the one or more of the second channel dimensions (e.g., length and/or width) of the second layer may be different.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Promoting public awareness of child and family health and wellness issues; promoting public awareness of the need to improve the quality of life for children; promoting public awareness of the need to teach parents and children how to cope with challenges, manage stress, and make healthy decisions; promoting public awareness of the need to teach parents and children how to build emotional intelligence, independence, confidence, and problem solving skills in children Providing a website featuring resources, namely, non-downloadable publications in the nature of magazines and brochures in the field of promoting child and family health and wellness, teaching parents and children how to cope with challenges, manage stress, and make healthy decisions, providing tips and strategies for building emotional intelligence, independence, confidence, and problem solving skills in children Providing a website featuring information about health, wellness and nutrition, namely, information promoting child and family health and wellness, teaching parents and children how to cope with challenges, manage stress, and make healthy decisions, providing wellness tips and strategies for building emotional intelligence, independence, confidence, and problem solving skills in children for healthcare purposes
Disclosed herein are novel variants of clotting factor IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.
This disclosure relates to a chimeric respiratory syncytial vims encoding a chimeric RSV and hMPV F protein and uses of the chimeric virus or components therein in a vaccine. In certain embodiments, this disclosure relates to a live attenuated vaccine comprising an RSV backbone substituting the F proteins of RSV, for a chimeric RSV and hMPV F protein.
Systems, methods, and devices for prohibiting contaminants from entering a central venous catheter connection are disclosed. A device described herein includes a first body section defining a first internal cavity and a second body section defining a second internal cavity. The second body section can be hingeably connected to the first body section. A first tubing notch is positioned at an end of at least one of the first body section or the second body section. The device has an open configuration and a closed configuration, and wherein, in the closed configuration, the first internal cavity and the second internal cavity are adjacent to create a connector cavity configured to contain a first connector.
The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/11 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring interpupillary distance or diameter of pupils
As an IV infiltration occurs and fluid leaks into surrounding tissues, several physiological changes are expected locally. The systems and methods described herein provide a scalable automated IV infiltration detection device to provide medical staff an early warning of a possible infiltration such that they can respond accordingly. The systems and methods capture the physiological state of the user at or around a peripheral catheter insertion site by incorporating one or more modalities of wearable sensing, processing the data collected from these wearable sensors, detecting the presence of extravascular fluid, and providing an indication to a medical professional.
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
C07D 311/68 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
C07D 311/68 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
81.
GALECTIN-9 SPECIFIC BINDING AGENTS FOR USE IN TREATING CANCER
This disclosure relates to uses of galectin-9 specific binding agents and chimeric antigen receptors in methods of treating cancer such as hematological cancers or solid tumors. In certain embodiments, the galectin-9 specific binding agent is a TIM3, CD44, CD40, CLEC7a (Dectin-1), or CD137 (4- IBB) extracellular domain, an anti-galectin-9 antibody, specific binding single chain antibody, fragment, or variant thereof. In certain embodiments, cancer treatment is a cell-based therapy using chimeric antigen receptors having a galectin-9 targeting sequence.
The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection. Specifically, the disclosure provides virus like-particles (VLPs) for use in inducing immunity to respiratory syncyhial virus (RSV) infections or symptoms thereof, wherein the VLP comprising a respiratory RSV matrix protein (M) and an RSV M2-1 protein, a glycoprotein (G), a fusion protein (F), and/or a phosphoprotein (P).
Provided herein are nucleic acids, vectors, and cells containing an expression-optimized codon that encodes a Munc13-4 polypeptide or a STXBP2 polypeptide. Also provided are methods of making and using the nucleic acids, vectors, and cells. Also provided herein are methods of treating of Hemophagocytic Lymphohistiocytosis (HLH) in a subject.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula:
or salts, esters, or prodrugs thereof, as provided herein.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
85.
Systems and methods for quantitative diagnosis of anemia
A smartphone-based hemoglobin (Hgb) assessment application quantitatively analyzes pallor in patient-sourced photos using image analysis algorithms to enable a noninvasive, accurate quantitative smartphone app for detecting anemia. A user takes a photo of his/her fingernail beds using the app and receives an accurate displayed Hgb level. Since fingernails do not contain melanocytes, the primary source of color of these anatomical features is blood Hgb. At the same time, quality control software minimizes the impact of common fingernail irregularities (e.g. leukonychia and camera flash reflection) on Hgb level measurement. Metadata recorded upon capturing the image is leveraged for determining a users' Hgb level thereby eliminating the need for external equipment. A personalized calibration of image data with measured Hgb levels improves the accuracy of the application.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
Methods and systems for treatment of feeding disorders in individuals by a multi-disciplinary team comprising medical, behavioral, nutritional, and oral-motor skill professionals and/or specialists. For example, in one embodiment, a subject may go through treatment that comprises four phases/process: screening, assessment, intervention, and discharge. The screening process may determine the subject's eligibility for the treatment. The assessment process may establish a baseline from which the specific treatment is determined. The intervention process generally implements the treatment through daily “doses” of treatment meal sessions. The discharge process may ensure that the treatment gains made during the intervention phase are carried into the subject's daily life.
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
87.
Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
This disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme or a vector encoding expression thereof, and a prodrug cleaved by said purine cleaving enzyme. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme, or a vector encoding expression thereof, in the absence of a prodrug cleaved by said purine cleaving enzyme.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
89.
BIONANOMECHANICAL DEVICES FOR USES IN EVALUATING LIQUID DYNAMICS
It is an object of this disclosure to provide systems, devices, and methods for the direct use of fluorescent reporters that measure multiaxial and dynamic shear flows that occur in vitro or in vivo across a surface of interest, where shear flows can be measured, quantified and/or correlated to physiological changes in cells or tissues in real time. In certain embodiments, this disclosure contemplates imaging or visualizing the shear field applied to a surface, e.g., a surface of cells or inner lining of a blood vessel, the lumen of pumping lymphatics, within the bile duct, vessels with significant leakage, inflamed endothelium, tumor vasculature, or other systems.
In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically, the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acid.
This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N′-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Stretchable condition-monitoring biopatch devices are disclosed. The stretchable condition-monitoring biopatches may include an elastomer layer. The elastomer layer may adhere to the skin without use of an adhesive. The devices described herein In may include stretchable electrodes configured to sense physiological potentials from the patient or subject. The device may include a stretchable circuit board. The stretchable electrodes may be in electrical communication with the stretchable circuit board via stretchable circuits. Methods for providing machine-learning neural networks are disclosed. These methods may include convolution neural networks that incorporate inception-type convolution units that may classify and diagnose conditions based on signals detected by the condition-monitoring biopatches.
A61B 5/259 - Means for maintaining electrode contact with the body using adhesive means, e.g. adhesive pads or tapes using conductive adhesive means, e.g. gels
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Healthcare services; pediatric healthcare services; providing information relating to child and family health, wellness, and nutritional issues via the internet
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Healthcare services; pediatric healthcare services; providing information relating to child and family health, wellness, and nutritional issues via the internet
The present disclosure relates to Zika vaccines. In certain embodiments, this disclosure relates to vaccine compositions for use in methods of protecting a human subject against Zika disease or infection, wherein said composition comprises a vaccinal for Zika such as a live attenuated or inactivated chimeric Zika virus; live attenuated Zika virus; an inactivated Zika virus; a replication-defective pseudo-infectious Zika virus; a Zika virus-like particle (VLP), a Zika protein or combinations thereof. In certain embodiments, the Zika vaccinal comprises or encodes altered polypeptide sequences disclosed herein.
Provided herein are recombinant AAV (rAAV) serotypes that are useful for targeting innate immune cells. In some embodiments, the rAAV are used to deliver genes encoding one or more receptors that can target the innate immune cells to diseased tissue of interest. In some aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of dendritic cells.
In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.
Provided herein are compounds, pharmaceutical compositions including such compounds, and methods of using such compounds to treat diseases or disorders associated with MDM2 activity.
A61K 31/4738 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
99.
Nucleic acids encoding clotting factor variants and their use
Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.
The systems and methods are provided that can efficiently and accurately generate 3D printed vascular models of a vascular network, including stenotic pulmonary arteries, capable of vascular perfusion. The method may include acquiring image(s) of an anatomy of interest that includes a target area. The method may further include generating a geometric model of a phantom of a vascular network to be bioprinted using the image(s). The phantom may include vascular segment(s), inlet(s), and outlet(s). Each inlet and each outlet may communicate with at least one vascular segment. The method may include generating a geometric model of a bioreactor to be 3D printed based on the geometric model of the phantom using one or more of assembly parameters, phantom parameters, or any combination thereof. The bioreactor model may include inlet(s), outlet(s), a chamber in which the phantom is disposed, an outer housing, and an interface bordering the chamber.
B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
B33Y 80/00 - Products made by additive manufacturing
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
